How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective

M. Shinfuku, H. Uchida, C. Tsutsumi, T. Suzuki, K. Watanabe, Y. Kimura, Y. Tsutsumi, K. Ishii, Y. Imasaka, M. Mimura, S. Kapur

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented. Methods: A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic. Results: Overall polypharmacy occurred in 79% patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0%, respectively. Once polypharmacy had started, it was continued until their final visit in >70% of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively). Conclusion: Routine practice deviates significantly from algorithms - with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalPharmacopsychiatry
Volume45
Issue number4
DOIs
Publication statusPublished - 2012 Jan 1

Keywords

  • concomitant drugs
  • polypharmacy
  • psychotropics
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective'. Together they form a unique fingerprint.

  • Cite this

    Shinfuku, M., Uchida, H., Tsutsumi, C., Suzuki, T., Watanabe, K., Kimura, Y., Tsutsumi, Y., Ishii, K., Imasaka, Y., Mimura, M., & Kapur, S. (2012). How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective. Pharmacopsychiatry, 45(4), 133-137. https://doi.org/10.1055/s-0031-1297934